Monday, June 23, 2025

Latest

PharmaTher Files With FDA For Pre-IND Meeting On Use Of Ketamine In Treatment Of Parkinson’s Disease

PharmaTher Inc (CSE: PHRM) this morning announced that it has filed a pre-investigational new drug meeting request, as well as having completed pre-IND briefing documents with that of the US Food and Drug Administration. The filings have been made in connection with the firms focus on clinical development of the use of ketamine in treating Parkinson’s Disease.

The filing that has been made by the company will also support the evaluation of a phase two clinical study on the use of ketamine to treat levodopa-induced dyskinesia that is associated with Parkinson’s Disease. The pre-IND meeting is viewed as a means of providing information to push forward with phase two clinical studies within the US.

Ketamine is currently an FDA-approved drug that contains a known safety profile. Preclinical data and case studies within Parkinson’s patients have shown that low doses of the compound have shown the potential to reduce levodopa-induced dyskinesia, which in layman terms is an involuntary movement disorder. The use of ketamine in such applications has also been indicated to reduce depression and improve on time.

“We are pleased to have taken this important step in advancing our ketamine program for Parkinson’s disease via the FDA regulatory pathway, which is part of our overall strategy of progressing our novel ketamine prescription-based therapies to treat neurological disorders for FDA approval. We look forward to finalizing our Phase 2 clinical study for ketamine in Parkinson’s disease and leveraging the pre-IND meeting to unlock additional value in our exclusive FDA-based ketamine programs in depression and pain.”

Fabio Chianelli, CEO of PharmaTher

PharmaThe last traded at $0.29 on the CSE.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Tudor Gold x American Creek: Consolidating A Massive Gold Project

Aura Minerals: The Era Dorada Underground PEA

Gold Is Now Smart Money’s End Game | Doug Casey

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

Pharmather Applies For Orphan Drug Status For Ketamine In Use Against Parkinson’s Disease

Pharmather Inc (CSE: PHRM) has filed for orphan drug designation with the US Food and...

Tuesday, October 20, 2020, 09:30:33 AM

PharmaTher Submits For Phase 2 Clinical Trial With FDA

PharmaTher Holdings (CSE: PHRM) is looked to complete a phase two clinical trial. The company...

Tuesday, April 20, 2021, 07:38:21 AM

Revive Therapeutics, Pharmather Partner On Psilocybin Cancer Research

Revive Therapeutics (CSE: RVV) and Pharmather Inc (CSE: PHRM) this morning jointly announced a research...

Wednesday, November 18, 2020, 07:30:40 AM

PharmaTher Secures Japanese Patent For Ketabet

PharmaTher Holdings (CSE: PHRM) announced today that it has been granted a Japanese patent for its...

Tuesday, November 30, 2021, 09:52:00 AM

Pharmather Files For Orphan Drug Status For Use Of Ketamine Against Postherpetic Neuralgia

Pharmather Inc (CSE: PHRM) this morning announced that it has filed for orphan drug status...

Tuesday, October 27, 2020, 08:42:25 AM